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Editorial on the Research Topic
Hereditary Spastic Paraplegias: Intersecting Molecular Pathways and Clinical Syndromes
Hereditary spastic paraplegias (HSPs) are a large group of rare neurologic conditions primarily
affecting the longest corticospinal axons, with the pathognomonic triad of lower limb spasticity,
weakness, and mild deep sensation impairment. Additional signs and symptoms are found in
patients with complex (or complicated) forms. In spite of its low incidence and prevalence, the
condition has attracted rapidly growing interest from the scientific community.
Why is a rare disorder initially described in the late nineteenth century by the German
neurologist Adolph Strümpell and barely covered by the scientific literature throughout most of
the twentieth century now exploding in terms of clinical, physiological, molecular and genetic
interest? Certainly, the advent of next generation sequencing and the rapid identification of
new disease genes play key roles. Indeed, the number of HSP disease loci is fast approaching
one hundred. The paradox of extreme genetic heterogeneity, still growing (∼40% of clinically
diagnosed patients still escape molecular characterization) in the face of a mostly stereotypical
clinical presentation, garners broad interest. Added to this is the conundrum of reconciling the
multiple diverse cellular pathogenic themes proposed, which has piqued the interest of both basic
and clinical scientists. It is thus not surprising that HSPs are among the conditions to which the
large European initiative “Solve rare diseases” (http://solve-rd.eu/) has directed its attention, and
there are also global efforts to gather data from dispersed clinical studies into structured, shared
databases to facilitate investigations. In this issue of Frontiers in Neuroscience, 11 leading research
groups from throughout the world discuss a diverse range of HSP topics, ranging from cellular and
animal models to clinical investigations, emphasizing links of different cellular pathogenic themes
to observable phenotypic and clinical manifestations.
The underlying physiopathologies of HSP dovetail with mechanisms currently in the spotlight
for other, more common, neurologic disorders. These include the dysregulation of lipid
metabolism, reviewed by Darios et al. in this issue and illustrated in detail by Sunderhaus et al. for
PNPLA6 (SPG39). Lipid homeostasis is important for membrane maintenance and trafficking as
well as synaptic and organelle functions, and alterations in the synthesis or degradation of various
classes of lipids can led to CNS pathologies, which is not surprising for a tissue so highly enriched
in lipids. Alterations of mitochondrial function, oxidative stress or impairment of axonal transport
can occur in someHSP forms directly due to lipidmetabolism impairment. On the other hand, lipid
alterations can be observed in HSP forms associated to mutations in genes apparently unrelated
to lipid metabolism, and the link between alterations of lipid metabolism and neurodegeneration
remains unclear for many forms of HSP.
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Endolysosomal functions are also commonly implicated in
HSP; and Allison et al. show here that some variants in the
MIT domain of the spastin protein do not directly affect its
microtubule severing activity, as demonstrated for most other
mutations, but rather alter endosomal tubule fission, molecule
sorting via the tubular-vesicular pathway and lysosomal
morphology, prefiguring future personalized “mutation-
oriented” therapies. In addition, most neurodegenerative
diseases have been considered for decades as resulting from
cell autonomous mechanisms, meaning that single pathological
events in neurons suffice to produce the disease. This has been
reconsidered in many neurodegenerative conditions with the
“neighborhood matters” concept, and HSP is no exception.
Ozdowski et al. demonstrate here the important contributions of
glial dysfunction to the synaptic defects in SPG4. They showed
that the synaptic anomalies due to spastin knock-out can be
reverted through Pak3 loss of function in glial cells; Pak3 is a
kinase crucial for actin distribution and cell mobility, particularly
important for glial projections at the neuromuscular junction.
While identification of human HSP causative genes has
opened new routes to understanding the pathogenic mechanisms
underlying these diseases, model organisms have proved
invaluable in understanding how these genes, and mutations
affecting them, affect neuronal function in whole organisms,
from both genetic and physiological perspectives. Genetically,
both Sunderhaus et al. and Montagna et al. use Drosophila
to assay effects of disease-associated mutations in human HSP
genes. Sunderhaus et al. show that HSP-causative alleles of
human PNPLA6 (SPG39) retain some biological functions in
transgenic flies, and Montagna et al. provide evidence for loss-
of-function effects of disease-causing mutations in atlastin-
1 (SPG3A). Transgenic targeted-expression tools were used
by Ozdowski et al. to show the potential for glial cells to
contribute to the phenotypes resulting from loss of spastin.
Many HSP proteins are structural or enzymatic components of
endoplasmic reticulum (ER) membrane, suggesting that axonal
ER dysfunction might be a key mechanism for HSP. Thus, Oliva
et al. and Napoli et al. characterize effects of HSP-related mutant
genotypes on ER Ca2+ handling (Oliva et al.) and ER stress
(Napoli et al.), and the latter study also shows pharmacological
effects on the phenotypes. While not yet translatable to patients,
the Napoli et al. study shows the potential of such models to
assess pharmacological target proteins and processes. Finally, this
collection contains two review articles that draw on genetic and
physiological work on model organisms. Naef et al. review the
genetic and cellular insights into complicated HSPs derived from
zebrafish studies, while Fowler et al. review how interactions
between organelles may be sites for some of the cellular defects
that contribute to HSP pathology.
The clinical perspective is addressed from two important
points of view: the search for clinically useful and efficient
biomarkers (Montanaro et al.) and the evaluation of the efficacy
of currently available interventions (Paparella et al.). The work
on the multimodal MRI is particularly intriguing. Besides
confirming the ability of so-called “advanced MRI” to capture
widespread structural alterations in the brains of HSP patients,
it provides the problematic finding of a paradoxical increase in
Fractional Anisotropy (reflecting in certain ways the degree of
order and organization of the axons within the central nervous
tissue) in the longitudinal assessment of these patients. The
interpretation of this finding is challenging. Some hypotheses
are given in the paper, but certainly this is an area where
information coming from studies on animal and cellular models
might offer insight. The paper on the efficacy and safety of
the approach combining chemodenervation with botulinum
toxin and intensive physiotherapy highlights the importance of
individualizing treatment solutions to the specific pattern of
spasticity and motor impairment presented by each patient. In a
condition characterized by wide heterogeneity of genes involved
and pathways deranged in the setting of a shared principal
phenotype (lower limb spasticity and weakness), this is a much
needed reminder that the unifying feature of spastic paraplegia
can mask subtle but clinically very relevant nuances that need to
be taken into consideration when planning interventional trials.
Again, a systematic appraisal of phenotypic patterns across the
different SPG types might reveal patterns coherent with data
emerging from the pathophysiology studies.
In summary, the goal of this scientific topic issue was
to provide an arena for encounters between basic science
advancements and clinical aspects in HSP. The topic has been
addressed from various perspectives, but it is noteworthy that in
addition to two papers overtly dedicated to the clinical approach,
at least four other papers approaching the topic from a basic
science perspective specifically mention the possible uses of these
insights toward the development of much needed new therapies.
This Research Topic issue in just a few months has attracted
well over 30,000 views, confirming the fervent interest across
the scientific and medical community for the HSPs. Indeed, the
crossroads that the issue sought to portray between molecular
pathways and clinical investigations looks more like a bridge,
linking the two worlds.
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